Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Sep 10, 2016 โ Oct 14, 2016
NCT ID
NCT03050619About Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs is a pre-clinical stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT03050619. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03050619 | Pre-clinical | Completed |
Competing Products
20 competing products in Type 2 Diabetes